Physician profile
George Durst
NPI 1174508378
$2,790.85
in general payments reported to CMS, 2019-2025
35 companies · $368 in 2025
The $368 reported for 2025 was more than what a typical Family Medicine provider received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $123 · 2020: $458 · 2021: $899 · 2022: $408 · 2023: $328 · 2024: $207 · 2025: $368.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $903.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $902.79 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $879.79 | 2021-2025 | Vraylar, Ubrelvy |
| Astrazeneca Pharmaceuticals LP | $211.40 | 2020-2023 | Farxiga |
| Lilly USA, LLC | $195.21 | 2020-2023 | Jardiance |
| Allergan, INC. | $161.64 | 2019-2020 | |
| Amgen INC. | $135.29 | 2020-2024 | Repatha |
| Axsome Therapeutics, INC. | $114.70 | 2025 | Auvelity |
| Pfizer INC. | $108.08 | 2021-2025 | |
| Arbor Pharmaceuticals, INC. | $104.96 | 2020-2021 | |
| Glaxosmithkline, LLC. | $83.79 | 2020-2024 | Arexvy, Shingrix |
| Takeda Pharmaceuticals U.S.A., INC. | $79.07 | 2020-2021 | |
| Biohaven Pharmaceuticals, INC. | $74.74 | 2021 | |
| Jazz Pharmaceuticals INC. | $73.56 | 2020-2021 | |
| Novo Nordisk INC | $58.70 | 2021-2025 | Wegovy, Rybelsus, Ozempic |
| Biohaven Pharmaceutical Holding Company LTD. | $56.82 | 2022 | |
| Gilead Sciences, INC. | $52.43 | 2024-2025 |
Show all 35 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amarin Pharma, INC. | $32.59 | 2020-2021 | |
| Mylan Specialty L.P. | $31.35 | 2021-2022 | |
| Eisai INC. | $27.98 | 2020-2021 | |
| Globus Medical, INC. | $24.01 | 2025 | Senza |
| Astellas Pharma US INC | $22.45 | 2023 | Veozah |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $22.14 | 2024 | Caplyta |
| Esperion Therapeutics, INC. | $22.06 | 2021 | |
| Azurity Pharmaceuticals, INC. | $22.00 | 2023 | Edarbi |
| Novartis Pharmaceuticals Corporation | $21.54 | 2022 | |
| Dynavax Technologies Corporation | $19.96 | 2024 | Heplisav-B |
| E.R. Squibb & Sons, L.L.C. | $18.31 | 2021 | |
| Amneal Pharmaceuticals LLC | $17.85 | 2024 | Unithroid |
| Teva Pharmaceuticals USA, INC. | $17.76 | 2020 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $16.64 | 2023 | Xifaxan |
| Biogen, INC. | $15.37 | 2021 | |
| Otsuka America Pharmaceutical, INC. | $15.33 | 2023 | Nuedexta |
| Merck Sharp & Dohme LLC | $14.94 | 2024 | Capvaxive, Gardasil 9, Gardasil |
| Bayer Healthcare Pharmaceuticals INC. | $14.22 | 2022 | |
| Kowa Pharmaceuticals America, INC. | $12.25 | 2020 | |
| Genentech USA, INC. | $11.92 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw George Durst listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.